Peter Sandercock

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1669313/publications.pdf

Version: 2024-02-01

116 12,810 43 110 papers citations h-index g-index

118 118 118 15105
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Framework for design and evaluation of complex interventions to improve health. BMJ: British Medical Journal, 2000, 321, 694-696.	2.4	2,664
2	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	6.3	1,971
3	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet, The, 2012, 379, 2352-2363.	6.3	1,018
4	Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet, The, 2012, 379, 2364-2372.	6.3	847
5	Indications for Early Aspirin Use in Acute Ischemic Stroke. Stroke, 2000, 31, 1240-1249.	1.0	567
6	Epileptic seizures after a first stroke: the Oxfordshire community stroke project. BMJ: British Medical Journal, 1997, 315, 1582-1587.	2.4	390
7	Blood Markers for the Prognosis of Ischemic Stroke. Stroke, 2009, 40, e380-9.	1.0	261
8	Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator. Stroke, 2012, 43, 2904-2909.	1.0	259
9	Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6. PLoS Medicine, 2009, 6, e1000145.	3.9	223
10	Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurology, The, 2009, 8, 908-917.	4.9	222
11	Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet, The, 2019, 393, 265-274.	6.3	213
12	Is the EuroQol a Valid Measure of Health-Related Quality of Life After Stroke?. Stroke, 1997, 28, 1876-1882.	1.0	212
13	Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurology, The, 2009, 8, 898-907.	4.9	196
14	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, The, 2016, 15, 925-933.	4.9	187
15	Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet, The, 2019, 393, 877-888.	6.3	178
16	Blood Biomarkers in the Diagnosis of Ischemic Stroke. Stroke, 2008, 39, 2902-2909.	1.0	162
17	Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ: British Medical Journal, 2008, 336, 376-379.	2.4	154
18	Sensible approaches for reducing clinical trial costs. Clinical Trials, 2008, 5, 75-84.	0.7	153

#	Article	IF	CITATIONS
19	Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome. Stroke, 2015, 46, 361-368.	1.0	142
20	Follow-up by mail in clinical trials: does questionnaire length matter?. Contemporary Clinical Trials, 2004, 25, 31-52.	2.0	138
21	Can Simple Questions Assess Outcome after Stroke?. Cerebrovascular Diseases, 1994, 4, 314-324.	0.8	120
22	Systematic reviews of animal experiments. Lancet, The, 2002, 360, 586.	6.3	117
23	The Use of Blood Biomarkers to Predict Poor Outcome After Acute Transient Ischemic Attack or Ischemic Stroke. Stroke, 2012, 43, 86-91.	1.0	111
24	Depressive Disorders in Long-Term Survivors of Stroke. British Journal of Psychiatry, 1994, 164, 380-386.	1.7	109
25	Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS Costs. Stroke, 2004, 35, 1490-1497.	1.0	109
26	Sensitivity and Specificity of the Hyperdense Artery Sign for Arterial Obstruction in Acute Ischemic Stroke. Stroke, 2015, 46, 102-107.	1.0	106
27	The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials, 2008, 9, 37.	0.7	86
28	Effects of Blood Pressure and Blood Pressure–Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke. Stroke, 2015, 46, 3362-3369.	1.0	83
29	Association of Circulating Inflammatory Markers With Recurrent Vascular Events After Stroke. Stroke, 2011, 42, 10-16.	1.0	77
30	How Do Scores on the EuroQol Relate to Scores on the SF-36 After Stroke?. Stroke, 1999, 30, 2146-2151.	1.0	75
31	Evidence-based practice for stroke. Lancet Neurology, The, 2009, 8, 308-309.	4.9	73
32	New Strategy to Reduce the Global Burden of Stroke. Stroke, 2015, 46, 1740-1747.	1.0	71
33	Hoover's sign for the diagnosis of functional weakness: A prospective unblinded cohort study in patients with suspected stroke. Journal of Psychosomatic Research, 2011, 71, 384-386.	1.2	67
34	Targeting Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Based on Risk of Intracranial Hemorrhage or Poor Functional Outcome. Stroke, 2014, 45, 1000-1006.	1.0	64
35	An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. Health Technology Assessment, 2014, 18, 1-368.	1.3	63
36	Third International Stroke Trial. International Journal of Stroke, 2006, 1, 172-176.	2.9	56

#	Article	IF	Citations
37	The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. Health Technology Assessment, 2015, 19, 1-90.	1.3	56
38	Causes of Death by Level of Dependency at 6 Months After Ischemic Stroke in 3 Large Cohorts. Stroke, 2009, 40, 1585-1589.	1.0	50
39	Length of Carotid Stenosis Predicts Peri-Procedural Stroke or Death and Restenosis in Patients Randomized to Endovascular Treatment or Endarterectomy. International Journal of Stroke, 2014, 9, 297-305.	2.9	49
40	Hospital management of acute ischemic stroke in China. Journal of Stroke and Cerebrovascular Diseases, 1997, 6, 361-367.	0.7	46
41	Why Calls for More Routine Carotid Stenting Are Currently Inappropriate. Stroke, 2013, 44, 1186-1190.	1.0	46
42	Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial. European Stroke Journal, 2021, 6, 222-228.	2.7	45
43	Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3. Stroke, 2015, 46, 2325-2327.	1.0	44
44	Blood Biomarkers for the Diagnosis of Acute Cerebrovascular Diseases: A Prospective Cohort Study. Cerebrovascular Diseases, 2011, 32, 141-147.	0.8	40
45	Functional Status Three Months after the First Ischemic Stroke Is Associated with Long-Term Outcome: Data from a Community-Based Cohort. Cerebrovascular Diseases, 2014, 38, 46-54.	0.8	40
46	European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. European Stroke Journal, 2016, 1, 6-19.	2.7	39
47	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials, 2011, 12, 252.	0.7	38
48	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. International Journal of Stroke, 2018, 13, 175-189.	2.9	36
49	The Effect of Graduated Compression Stockings on Long-term Outcomes After Stroke. Stroke, 2013, 44, 1075-1079.	1.0	35
50	Impact of Stroke Syndrome and Stroke Severity on the Process of Consent in the Third International Stroke Trial. Cerebrovascular Diseases, 2006, 21, 348-352.	0.8	34
51	Increasing value and reducing waste in stroke research. Lancet Neurology, The, 2017, 16, 399-408.	4.9	33
52	Negative Results: Why Do they Need to be Published?. International Journal of Stroke, 2012, 7, 32-33.	2.9	32
53	Statistical Analysis Plan for the Third International Stroke Trial (IST-3); Part of a †Thread†Mof Reports of the Trial. International Journal of Stroke, 2012, 7, 186-187.	2.9	31
54	Cut stroke in half: Polypill for primary prevention in stroke. International Journal of Stroke, 2018, 13, 633-647.	2.9	29

#	Article	IF	Citations
55	The brain, the science and the media. EMBO Reports, 2011, 12, 630-636.	2.0	27
56	Clinical and imaging services for TIA and minor stroke: results of two surveys of practice across the UK. BMJ Open, 2013, 3, e003359.	0.8	26
57	Full Heparin Anticoagulation Should Not Be Used in Acute Ischemic Stroke. Stroke, 2003, 34, 231-232.	1.0	25
58	Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial). Stroke, 2016, 47, 2959-2965.	1.0	25
59	Can clinical features distinguish between immobile patients with stroke at high and low risk of deep vein thrombosis? Statistical modelling based on the CLOTS trials cohorts. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1067-1073.	0.9	24
60	Intermittent pneumatic compression in patients with stroke – Authors' reply. Lancet, The, 2013, 382, 1481-1482.	6.3	23
61	"Can It Read My Mind?―– What Do the Public and Experts Think of the Current (Mis)Uses of Neuroimaging?. PLoS ONE, 2011, 6, e25829.	1.1	22
62	The Authors Say: †The Data Are Not So Robust because of Heterogeneity' – So, How Should I Deal with This Systematic Review?. Cerebrovascular Diseases, 2011, 31, 615-620.	0.8	20
63	Conceptual framework for establishing the African Stroke Organization. International Journal of Stroke, 2021, 16, 93-99.	2.9	20
64	Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on All-Cause Mortality (Third) Tj ETQq0 0 0 rgBT /Ove	erlock 10	Tf 50 382 Td
65	Review and prioritization of stroke research recommendations to address the mission of the World Stroke Organization: a call to action from the WSO Research Committee. International Journal of Stroke, 2015, 10, 4-9.	2.9	14
66	A telephone hotline for transient ischaemic attack and stroke: prospective audit of a model to improve rapid access to specialist stroke care. BMJ: British Medical Journal, 2010, 341, c3265-c3265.	2.4	12
67	Improving Clinical Detection of Acute Lacunar Stroke. Stroke, 2020, 51, 1411-1418.	1.0	11
68	Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: Report of the Therapeutics and Technology Subcommittee of the American Academy of Neurology. Neurology, 2011, 76, 2036-2038.	1.5	10
69	Feasibility and diagnostic accuracy of using brain attenuation changes on CT to estimate time of ischemic stroke onset. Neuroradiology, 2021, 63, 869-878.	1.1	10
70	Antiplatelet Therapy with Aspirin in Acute Ischaemic Stroke. Thrombosis and Haemostasis, 1997, 78, 180-182.	1.8	10
71	Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment, 2020, 24, 1-94.	1.3	10
72	Intravenous Unfractionated Heparin in Patients With Acute Ischemic Stroke: A Treatment to Be Used in the Context of Randomized Trials Only. Stroke, 2001, 32, 579-579.	1.0	9

#	Article	IF	CITATIONS
73	Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation. Stroke, 2006, 37, 3054-3055.	1.0	9
74	Anticoagulants for Acute Ischemic Stroke. Stroke, 2009, 40, .	1.0	9
7 5	Does intermittent pneumatic compression reduce the risk of post stroke deep vein thrombosis? The CLOTS 3 trial: study protocol for a randomized controlled trial. Trials, 2012, 13, 26.	0.7	9
76	Does intermittent pneumatic compression reduce the risk of post stroke deep vein thrombosis? The CLOTS 3 trial: statistical analysis plan. Trials, 2013, 14, 66.	0.7	9
77	How many Patients might Receive Thrombolytic Therapy in the Light of the ECASS-3 and IST-3 Data?. International Journal of Stroke, 2010, 5, 430-431.	2.9	8
78	Prevention of venous thromboembolism after acute ischaemic stroke. Lancet, The, 2007, 370, 735-736.	6.3	7
79	How can the World Stroke Organization (WSO) optimize education in stroke medicine around the world? Report of the 2018 WSO Global Stroke Stakeholder Workshop. International Journal of Stroke, 2019, 14, 803-805.	2.9	7
80	Clinical diagnosis of TIA or minor stroke and prognosis in patients with neurological symptoms: A rapid access clinic cohort. PLoS ONE, 2019, 14, e0210452.	1.1	7
81	EPITHET—where next?. Lancet Neurology, The, 2008, 7, 570-571.	4.9	6
82	Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke. Stroke and Vascular Neurology, 2021, 6, 238-243.	1.5	6
83	â€~Yes' or â€~No' to Routine Statins After Subarachnoid Hemorrhage to Prevent Delayed Cerebral Ischaem Vasospasm, and Death?. Stroke, 2010, 41, e1-2.	nia 1:0	5
84	IST-3 stroke trial data available. Lancet, The, 2016, 387, 1904.	6.3	5
85	Blood pressure variability and leukoaraiosis in acute ischemic stroke. International Journal of Stroke, 2018, 13, 473-480.	2.9	5
86	Fluoxetine and Fractures After Stroke. Stroke, 2019, 50, 3280-3282.	1.0	5
87	Top 10 global educational topics in stroke: A survey by the World Stroke Organization. International Journal of Stroke, 2019, 14, 843-849.	2.9	5
88	Factors influencing the use of different methods of consent in a randomized acute stroke trial: The Third International Stroke Trial (IST-3). International Journal of Stroke, 2022, 17, 553-558.	2.9	5
89	Collaborative Worldwide Overviews of Randomized Trials. Annals of the New York Academy of Sciences, 1993, 703, 149-155.	1.8	4
90	Antiplatelet Therapy in Acute Cerebral Ischaemia. Stroke, 1999, 30, 2238-2248.	1.0	4

#	Article	IF	Citations
91	â€Where are we Now with Intravenous Thrombolysis for Acute Ischaemic Stroke'?. International Journal of Stroke, 2010, 5, 381-382.	2.9	4
92	Why the US Center for Medicare and Medicaid Services Should Not Extend Reimbursement Indications for Carotid Artery Angioplasty/Stenting. Angiology, 2012, 63, 639-644.	0.8	4
93	Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting. Brain and Behavior, 2012, 2, 200-207.	1.0	4
94	Which stroke patients gain most from intermittent pneumatic compression: further analyses of the CLOTS 3 trial. International Journal of Stroke, 2015, 10, 103-107.	2.9	4
95	How to do high-quality clinical research 1: First steps. International Journal of Stroke, 2018, 13, 121-128.	2.9	4
96	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. British Journal of Haematology, 2010, 148, 339-340.	1.2	3
97	Third International Stroke Trial 3. Current Opinion in Neurology, 2014, 27, 8-12.	1.8	3
98	Venous Thromboembolism After Acute Stroke. Stroke, 2001, 32, 1443-1448.	1.0	2
99	A fainting mechanic. Lancet, The, 2002, 360, 305.	6.3	2
100	Physical Methods for Preventing Deep Vein Thrombosis in Stroke. Stroke, 2005, 36, 1102-1103.	1.0	2
101	Vitamin B supplements for prevention of stroke. Lancet Neurology, The, 2010, 9, 842-843.	4.9	2
102	Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting. Vascular, 2012, 20, 1-7.	0.4	2
103	Alteplase for ischaemic stroke—responses. Lancet, The, 2014, 384, 660-661.	6.3	2
104	Contents of the Cochrane Library on the Organisation of Stroke Services. Cerebrovascular Diseases, 2003, 15, 2-4.	0.8	1
105	Anticoagulants for Acute Ischemic Stroke. Chest, 2008, 134, 466.	0.4	1
106	Carotid stenosisâ€"surgery or stenting to prevent stroke?. Nature Reviews Neurology, 2010, 6, 647-648.	4.9	1
107	Thrombolysis in acute ischaemic stroke – Authors' reply. Lancet, The, 2012, 380, 1054-1055.	6.3	1
108	Is the 'liberation procedure' for multiple sclerosis really liberating?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 362-362.	0.9	1

#	Article	IF	CITATIONS
109	World Stroke Day – a day of global action. International Journal of Stroke, 2018, 13, 779-779.	2.9	1
110	Eivind Berge, MD, PhD, 1964–2020. Stroke, 2020, 51, 1353-1355.	1.0	1
111	Response to Letter by Sanossian et al. Stroke, 2006, 37, 2661-2661.	1.0	O
112	The Johann Jakob Wepfer Award 2010 of the European Stroke Conference to Professor Jan van Gijn. Cerebrovascular Diseases, 2010, 30, 327-329.	0.8	0
113	Should mechanical embolectomy devices be used in routine clinical practice?. Journal of Neural Transmission, 2011, 118, 1131-1138.	1.4	0
114	In Memoriam Eivind Berge, MD, PhD, 1964–2020. European Stroke Journal, 2020, 5, 113-114.	2.7	0
115	In memoriam Eivind Berge, MD, PhD, 1964–2020: cardiologist, trialist and hypertension/stroke researcher. Journal of Hypertension, 2020, 38, 1199-1200.	0.3	0
116	Schlaganfall: PrimÃrbehandlung. Vasa - European Journal of Vascular Medicine, 2001, 30, 305-310.	0.6	0